Trial Profile
A Phase-3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Compare Efficacy and Safety of Pomalidomide in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis and Red Blood Cell-Transfusion-Dependence
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 23 Dec 2021
Price :
$35
*
At a glance
- Drugs Pomalidomide (Primary)
- Indications Essential thrombocythaemia; Myelofibrosis; Polycythaemia vera
- Focus Registrational; Therapeutic Use
- Acronyms RESUME
- Sponsors Celgene Corporation
- 17 Jan 2019 Status changed from active, no longer recruiting to completed.
- 04 Dec 2018 Results evaluating the genetics of transfusion-dependent myelofibrosis patients and correlate with clinical characteristics, outcome and therapy response presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
- 03 Sep 2018 Trial has been completed in Poland. (End date: 2018-05-15).